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The hypothesis that heparin-coated perfusion circuits reduce thrombin 
formation and activity; fibrinolysis; and platelet, complement, and neutro- 
phil activation was tested in 20 consecutive, randomized adults who had 
cardiopulmonary bypass. Twenty identical perfusion systems were used; in 
10, all blood-contacting surfaces were coated with partially degraded 
heparin (Carmeda process; Medtronic Cardiopulmonary, Anaheim, Calif.). 
All patients received a 300 U/kg dose of heparin. Activated clotting times 
were maintained longer than 400 seconds. Cardiopulmonary bypass lasted 
36 to 244 minutes. Blood samples for platelet count, platelet response to 
adenosine diphosphate, plasma iß-thromboglobulin, inactivated comple- 
ment 3b, neutrophil elastase, fibrinopeptide A, prothrombin fragment F1.2, 
thrombin-antithrombin complex, tissue plasminogen activator, plasmino- 
gen activator inhibitor-1, plasmin «2-antiplasmin complex, and D-dimer 
were obtained at these times: after heparin was given, 5 and 30 minutes 
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after cardiopulmonary bypass was started, within 5 minutes after bypass 
was stopped, and 15 minutes after protamine was given. After cardiopul- 
monary bypass, tubing segments were analyzed for surface-adsorbed anti- 
thrombin, fibrinogen, factor XII, and von Willebrand factor by radioimmu- 
noassay. Heparin-coated circuits significantly (p < 0.001) reduced platelet 
adhesion and maintained platelet sensitivity to adenosine diphosphate (p = 
0.015), but did not reduce release of lB-thromboglobulin. There were no 
significant differences between groups at any time for fibrinopeptide.4, prothrom- 
bin fragment F1.2, fr thrombin-antithrombin complex fr in the markers for 
fibrinolysis: D-dimer, tissue plasminogen activator, plasminogen activator inhib- 
itor-1, and «2-antiplasmin complex. In both groups, concentrations of 
prothrombin fragment F1.2 and thrombin-antithrombin complex increased 
progressively and significantly during cardiopulmonary bypass and after 
protamine was given. Concentrations of D-dimer, «2-antiplasmin complex, 
and plasminogen activator inhibitor-1 also increased significantly during 
bypass in both groups. Fibrinopeptide A levels did not increase during 
bypass but in both groups increased significantly after protamine was 
given. No significant ditferences were observed between groups for levels of 
inactivated complement 3b fr neutrophil elastase. Radioimmunoassay 
showed a significant increase in surface-adsorbed antithrombin on coated 
circuits but no significant ditferences between groups for other proteins. We 
conclude that heparin-coated circuits used with standard doses of systemic 
heparin reduce platelet adhesion and improve platelet function but do not 
produce a meaningful anticoagulant effect during clinical cardiopulmonary 
bypass. The data do not support the practice of reducing systemic heparin 
doses during cardiac operations with heparin-coated extracorporeal perfu- 
sion circuitry. (J THORAC CARDIOVASC SURG 1996;111:1-12) 
0 ardiopulmonary bypass (CPB) produces a mas- sive thrombotic stimulus that is only partially 
suppressed by doses of heparin (3 mg/kg) that are 
two to three times those used to treat other throm- 
botic diseases. Despite activated clotting times of 
more than 400 seconds, thrombin is produced and 
increases progressively during CPB in every pa- 
tient. 1'2 Thrombin is a powerful protease 3 that 
primarily cleaves fibrinogen to fibrin, directly acti- 
vates platelets by means of a specific thrombin 
receptor, 4 and stimulates endothelial cells to pro- 
duce tissue plasminogen activator. 5 Formation of 
thrombin is directly related to production of fibrin, 
platelet dysfunction, and fibrinolysis associated with 
CPB. 
Over the past decade, numerous studies have 
suggested that heparin-coated extracorporeal perfu- 
sion circuits are "more biocompatible" (i.e., activate 
blood elements less strongly) than uncoated sys- 
tems. 642 Some of these studies indicate that hepa- 
rin-coated circuits reduce complement activation, ('-9 
reduce platelet 8' 1~ and neutrophil 7 activation, and 
reduce the need for standard doses of hepa- 
rin.9, 12, 13 The elficacy of heparin-coated surfaces 
with respect o complement, platelet, and leukocyte 
activation relates to the "inflammatory response" 
and morbidity of CPB. However, if standard doses 
of systemic heparin are reduced, the anticoagulant 
efficacy of heparin-coated perfusion circuits relates 
directly to the safety and mortality of CPB. 
This study was designed to determine the effect of 
heparin-coated perfusion circuitry on thrombin pro- 
duction and activity; fibrinolysis; platelet, neutro- 
phil, and complement activation; and surface ad- 
sorption of selected plasma proteins during clinical 
cardiac operations in adults. Because thrombin is 
formed during CPB even with standard doses of 
systemic heparin, we tested the hypothesis that use 
of heparin-coated perfusion circuitry reduces throm- 
bin formation and activity during CPB and has an 
anticoagulant effect. 
Methods 
Over a 2-month period, 20 consecutive (with one ex- 
ception), consenting patients who had cardiac operations 
during regular weekday hours were randomized by card 
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drawing into two groups--a control group in which the 
perfusion circuitry was not coated with heparin and a 
group in which the perfusion circuitry was coated with 
heparin. The study was approved by the Human Research 
Committee of the University of Pennsylvania. The ex- 
cluded patient had postinfarction angina, two previous 
operations, a preoperative intraaortic balloon pump, and 
mechanical circulatory assistance after revascularization. 
No other patient was excluded for any reason. All patients 
whose blood samples could be processed during regular 
weekday hours were asked to join the study and none 
refused. 
Twenty identical sterile perfusion circuits were assem- 
bled consisting of a soft-shell venous reservoir (model 
MVR1600, Medtronic Cardiopulmonary, Anaheim, 
Calif.), a centrifugal blood pump (Bio Pump model BP-80, 
Medtronic Bio--Medicus, Eden Prairie, Minn.), a hollow- 
fiber membrane oxygenator (Maxima model 1380, 
Medtronic Cardiopulmonary), and a 40/xm arterial filter 
(Intersept model M40, Medtronic Card~opulmonary). The 
pump and table packs of medical-grade polyvinylchloride 
tubing (Medtronic Cardiopulmonary) ~ncluded two lines 
for suction and one line for actively venting the left side of 
the heart (model 14622, Sarns 3M Health Care, Ann 
Arbor, Mich.) with blood returning to a filtered cardiot- 
omy reservoir (Intersept model 1351, Medtronic Cardio- 
pulmonary). For all patients a 4:1 blood cardioplegia 
system (model 5328, Gish Biomedical, Irvine, Calif.) was 
used to administer cardioplegic solution, both antegradely 
through the aortic root and retrogradely through the 
coronary sinus (cannula model 94215, DLP, Grand Rap- 
ids, Mich.). The aorta was cannulated with a 24F aortic 
cannula (m0del 4335, Sarns 3M Health Care, Ann Arbor, 
Mich.), and ivenous return was achieved with a two-stage 
venous catheter (model TR3651, Research Medical, Mid- 
vale, Utah) in all but four patients. These latter patients 
required bicaval cannulation (Research Medical). 
In 10 peffusion circuits, all components hat contacted 
blood were completely coated with the heparin-bonded 
Carmeda BioActive Surface (Medtronic Cardiopulmo- 
nary). The heparin coating included all cannulas, reser- 
voirs, tubing, connectors, and components of the system; 
only the Cell Saver System (Haemonetics, Braintree, 
Mass.) was :not coated (explained later). Because the 
packaged retrograde cardioplegia catheter (model 94215, 
DLP, Grand Rapids, Mich.) cannot be coated, a different 
catheter (model RC 2012 MIß, Research Medical), which 
was coated by Medtronic Cardiopulmonary, was used with 
the coated circuits. The Carmeda process covalently binds 
partially degraded heparin to aminated biomaterial sur- 
faces by reduction with sodium cyanoborohydride.~ 4 Con- 
trol perfusion drcuits appeared identical and the operat- 
ing surgeon did not know whether aheparin-coated circuit 
was used until the retrograde cardioplegia catheter was 
inserted, 
In all patients, intraoperative autotransfusion was used 
to collect and process hed blood from the operative field 
with the use Of an uncoated autologons Cell Saver System 
(model 243, Haemonetics) composed of two suction lines 
and an unfiltered cardiotomy reservoir (model MCR4000, 
Medtronic Cardiopulmonary). Each unit of packed red 
blood cells salvaged through this system was washed with 
1 L of normal saline solution before filtered reinfusion. 
All patients received isoflurane (Forane) anesthesia 
and vancomycin and cefazolin. Anesthesia was induced 
with midazolam in seven patients and with fentanyl in 13. 
Eighteen had pancuronium bromide. All except one had 
Swan-Ganz catheters (Baxter Healthcare Corp, Edwards 
Division, Santa Ana, Calif.), and all had arterial catheters. 
After anesthesia, intubation, and midline sternotomy, all 
patients received an intravenous dose of bovine lung 
heparin, 300 U/kg, before cannulation. Activated clotting 
times were measured (Hemochron model 801, Interna- 
tional Technidyne Corp., Edison, N.J.) at baseline, after 
administration of heparin before the start of CPB, and 
every 30 minutes during CPB. If necessary, additional 
boluses of heparin were given to maintain clotting times 
longer than 400 seconds throughout the period of CPB. 
The left ventricle was vented from the right superior 
pulmonary vein-left atrial junction in all patients except 
those with bicaval cannulation. 
Sixteen patients were cooled to a mean nasopharyngeal 
temperature of 30.6 ° -+ 0.7 ° C (standard error). The four 
patients who had pulmonary thromboembolectomy were 
cooled to 12 ° to 14.9 ° C and each ad four or five periods 
of circulatory arrest for 11 to 14 minutes that totaled 46 to 
69 minutes (mean 54.5 ± 5 minutes). After aortic clamp- 
ing all hearts were arrested with intermittent, cold blood, 
potassium cardioplegic solution administered in an ante- 
grade fashion; alternating retrograde cardioplegia was 
used in all except he patients who required thromboem- 
bolectomy and one patient with an atrial septal defect. 
Myocardial temperature was monitored and kept between 
8 ° and 14 ° C. Additional surface cooling with cold saline 
solution was used to maintain myocardial hypothermia. 
All field blood was returned either directly to the perfu- 
sion system or to the Cell Saver System (Haemonetics). 
Blood samples (20 ml) were obtained from the arterial 
catheter 5 minutes after heparin was administered, 5 and 
30 minutes after the start of CPB, approximately 5 min- 
utes before CPB was stopped, and 15 minutes after 
protamine was given. After wound closure, chest tube 
drainage was measured hourly for 24 hours and returned 
to the patient hrough an autotransfusion system (Pleur- 
evac model A-7050-ATS, Deknatel, Inc., Fall River, 
Mass.). 
In 12 patients (six from each group), 5 to 7 cm lengths 
of both venous and arterial tubing were excised from the 
perfusion circuit immediately after the operation and 
preserved in 2.5% buffered glutaraldehyde solution. The 
presence of four surface-adsorbed proteins--antithrom- 
bin, fibrinogen, factor XII, and von Willebrand factor-- 
was detected by radioimmunoassay (RIA) 15 in all sam- 
ples. 
Whole blood platelet counts were obtained in duplicate 
with a hemocytometer by means of phase microscopy. 
Platelet aggregation was measured in response to adeno- 
sine diphosphate in platelet-rich plasma. 1«» The number of 
platelets in platelet-rich plasma was normalized to 
150,000//xL in all samples to standardize aggregation. 
Threshold doses of adenosine diphosphate were deter- 
mined as the lowest dose of agent able to produce biphasic 
aggregation of 62.5% or more after 5 minutes in control 
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Table I. Patient descriptors and operations 
Heparin 
Control surface 
Descriptor (n = 10) (n = 10) 
Age (yr) (mean ± SEM) 64.8 ± 4.1 61.0 +_ 3.5 
Male/female 5/5 6/4 
Operation 
Myocardial revascularization 
First operation 4 4 
Second operation 1 
Valve repair/replacement 
Aortic 3 
Mitral 1 1 
Both 1 
Pulmonary thromboembolectomy 2 1 
With CABG ×3 1 
Closure of atriat secundum 1 
defect 
Aortic crossclamp time (min) 81.0 -+ 14.8 80.0 ± 12.4 
Duration of CPB (min) 121 _+ 20.0* 115.4 ± 15.7" 
Mean ± SEM 
Range (min) 36-211 71-216 
CABG, Coronary artery bypass grafting; SEM, standard error of the mean. 
*Includes periods of circnlatory arrest. 
samples. Threshold doses of adenosine diphosphate were 
then used to measure aggregation as a function of percent 
light transmittance in subsequent samples. An RIA was 
used to measure plasma levels of platelet 13-thrombo - 
globulin] 7 Plasma neutrophil elastase 18 and inactivated 
complement 3b, 19 a marker for complement activation, 
were measured by means of indirect competitive enzyme- 
linked immunosorbent assays (Quidel Inc., San Diego, 
Calif., for inactivated complement 3b). Enzyme-linked 
immunosorbent assays for fibrinopeptide A (American 
Bioproducts, Parsipanny, N.J.), 2° D-dimer (American Di- 
agnostica Inc., Greenwich, Conn.), 21 F1.2, a marker of 
prothrombin cleavage (Behring Diagnostics Inc, West- 
wood, Mass.), 22 and thrombin-antithrombin complex 
(Behring Diagnostics Inc.) 23 were performed according to 
instructions. Tissue plasminogen activator 24 and plasmin- 
ogen activator inhibitor-125 were measured by enzyme- 
linked immonoassay kits from American Diagnostica Inc.; 
plasmin c~2-antiplasmin was also measured by enzyme- 
linked immunoassay (Behring Diagnostics Inc.). 26 
For RIAs of adsorbed proteins, tubing samples were cut 
into 1 cm length rings and bisected twice into quarter 
segments. Each quarter segment had an inner surface area 
of 0.8 cm 2. Duplicate tubing samples were placed in glass 
tubes for RIA of each adsorbed protein. Samples were 
rinsed twice with phosphate-buffered saline solution 
(PBS) (1000-3, Sigma Chemical Company, St. Louis, Mo.) 
followed by addition of 2 ml of milk solution (15% nonfat 
dry milk in PBS with a 2 mmol/L concentration of sodium 
ethylenediaminetetraacetic acid). Samples were refriger- 
ated overnight and rinsed three times with PBS. Primary 
antibodies and rabbit antihuman immunoglobulin G frac- 
tions (10 mg/ml stock) were diluted 1:500 in PBS la 
containing 1% chicken egg albumin (ovalbumin), and i ml 
was added to each sample for 60 minutes at 37 ° C. 
Samples were again rinsed three times with PBS and the 
Table I I .  Relevant drugs, blood losses, and 
transfusions 
Control Coated 
(n = 10) (n - 10) 
Total heparin 23,250 _+ 3,374 32,150 ± 3,106 
(units in OR) 
Total protamine 134 _+ 13.3 183 ± 15.5" 
(mg or OR) 
Chest tube drainage 555 +_ 83t 780 ± 213 
(ml in 24 hr) 
Mean + SEM 
Range (ml) 175 - 1025 312 - 2620 
Blood product ransfusions 
(units in hospital) 
Packed cells 24t 25 
Fresh frozen plasma 5? 13 
Platelet units 6? 24 
OR, Operating room; SEM,, standard error of the rnean. 
*p < 0.05. 
tExcludes data from one patient. 
milk solution was added for storage overnight at 4 ° C. 
After each sample was rinsed three times with PBS, 1 ml 
of ~~»I-labeled goat antirabbit mmunoglobulin G (7/zCi/ 
ml, 250,000 cpm) was added to each sample for 60 minutes 
at 37 ° C. After incubation, samples were rinsed three 
" times with PBS, placed into a clean test tube, and counted 
in a gamma counter. 15 Counts of 125I-labeled goat anti- 
rabbit immunoglobulin G bound to the primary antibody 
of each target protein and a control count (1% ovalbumin/ 
PBS) were recorded. Control counts were subtracted from 
counts recorded for each target protein. 
Data are expressed as mean and standard error of the 
mean. Comparisons to "After heparin, before CPB" at 
different time intervals within groups were made by means 
of the paired t statistic. Comparisons between groups were 
made with the use of the t statistic for independent 
samples with the Bonferroni correction for multiple com- 
parisons (SYSTAT for Windows 5, SYSTAT, Inc., Evans- 
ton, Ill.) and by analysis of variance for repeated measures 
(SPSS for Windows 6.1, SPSS, Inc., Chicago, Ill.). The t 
statistic shows significant differences between groups at 
specific time points; the analysis of variance compares the 
differences between the ?wo groups for all samples ob- 
tained after CPB began. A p value less than 0.05 is 
considered significant. 
Results 
Descript ive data for the 20 patients appear  in 
Table I. There were no significant differences be- 
tween groups in the demographic  data. Three pa- 
tients (one from the control  group; two from the 
coated group) had aspirin within 5 days of the 
operat ion.  Six patients (four control) received hep- 
arin intravenously or subcutaneously and one con- 
trol pat ient received warfarin sodium (Coumadin)  
before the operat ion.  
Twenty- four -hour  postoperat ive blood loss, hep- 
arin and protamine doses, and autologous b lood and 
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Table III. Blood and plasma concentrations (means +_ standard error) 
After heparin, 
before CPB 5 min CPB 30 min CPB After CPB After protamine 
Measurement Control Coated Control Coated Control Coated Control Coated Control Coated p* 
Platelet count 98.5 106.5t 76 .2§  106.5t 69.6§ 102.8 78.5:~ 101.4 78.8:) 91.4 0.001 
(% of initial count) _+2.1 _+3.2 _+3.1 _+7.2 _+6.1 _+11.3 _+8.5 _+13.0 +7.6 +10.5 
Platelet aggregation 102.7 106.9 88.2§ 101.6 79.9§ 98.0 74 .25  89.35 57.1§ 75.4:~ 0.015 
(% light transmittance) _+5.0 _+6.1 _+5.0 -+5.6 _+8.6 _+8.0 _+9.8 _+15.0 -+8.3 -+10.0 
Plasma/3-thromboglobulin 9.3 10.1 15.2:) 11.6 21.2§ 13.6:~ 214§ 226.1§ 198.3§ 220.3§ 0.789 
(b~g/ml) _+1.0 _+0.7 _+1.9 _+1.4 _+2.4 _+1.3 _+32.1 _+40.5 _+36.4 +11.5 
F1.2 (nm) 2.3 2.3 3.4§ 3.1§ 3.8§ 3.4§ 5.5§ 5.7§ 5.6§ 6.2§ 0.965 
+0.15 --0.18 +0.39 -+0.25 -+0.40 --0.35 -+0.60 _+0.76 _+0.54 -+0.75 
FPA (hg/tal) 12.4 8.5 7.6:) 6.9 4.9§ 2.45 8.7 6.2 30.2§ 28.71§ 0.378 
+2.2 +2.6 +1.5 +2.7 1.5 +0.6 +2.7 _+1.7 _+4.8 _+4.4 
TAT (>g/L) 14.6 12.1 37.0§ 27.9§ 39 .6§  27 .5§  51.3§ 51.6 51.1§ 54.4§ 0.169 
_+1.8 _+1.7 -+5.9 -+4.0 _+5.3 -+3.3 _+3.9 -+4.8 _+4.2 +4.0 
D-dimer (mg/L) 0.26 0.26 0.36 0.26 0.43 0.28 0.82:)  0.65§ 0.66:) 0.66§ 0.265 
-+0.04 _+0.03 _+0.11 _+0.03 _+0.13 _+0.03 _+0.23 _+0.11 _+0.18 _+0.08 
t-PA (ng/m]) 11.7 7.6 9.4 6.6 12.5 8.8 12.4 12.2§ 14.5:) 14.1§ 0.176 
_+2.1 _+0.8 _+1.8 _+0.5 _+2.6 -+0.4 _+1.9 -+1.0 +1.5 -+1.2 
PAI-1 (ng/ml) 36.3 34.7 28.9 26.45 40.4 33.4 48 .9§  48.6§ 49.4§ 57.2§ 0.877 
_+5.3 _+5.4 _+3.9 _+3.7 _+4.5 _+5.0 _+4.9 _+4.8 _+5.6 -+3.1 
APP (ng/m!) 884 696 852 593 1712 822 2018§  1502§ 1998§  1632§ 0.013 
+166 -+63 +132 +75 -+561 +136 +330 --210 _+317 _+211 
Elastase (ng/ml) 67.2 75.0 64.0 53.0 88.1:~ 71.0 127.6§ 96.4 139.2§ 120.0:) 0.533 
-+11.5 -+15.4 -+10.3 -+9.6 -+6.0 +12.4 -+11.1 -+23.8 -+15.3 _+24.8 
iC3b (/zg/m!) 33.8 47.4 15.8~ 27.1 18.2:) 36.8 17.6 24.9 30.5 34.8 0.118 
_+5.8 _+11.8 _+2.1 _+7.1 _+1.6 _+12.1 _+1.6 _+2.4 -+3.5 -+5.1 
Hematocrit value (%) 32.7 35.6 21.5 24.4 21.6 25.1 24.0 23.7 23.6 25.1 
-+1.8 _+2.5 -+1.4 _+1.6 _+1.6 -+1.7 _+1.3 _+1.6 -+1.0 +1.7 
FI.2, Prothrombin fragment F1.2; FPA, fibrinogen peptide A; TAT, thrombin-antithrombin complex; D-dimer, fibrin fragment, D-dimer; Elastase, neutrophil 
elastase; iC3b, inactivated C3b; t-PA, tissue plasminogen activator; PAI-1, plasminogen activator inhibitor-1, APP, plasmin c~z-antiplasmin complex. 
~p Value for F statistic by analysis of variance for repeated measures. Baseline date (after heparin, before CPB) were excluded. 
tP < 0.01 -+ standard error, between-groups t statistic with Bonferroni correction. 
8p < 0.05 -+ standard error, within groups, compared with "after heparin, before CPB." 
§p < 0.01 -- standard error, within groups, compared with "after heparin, before CPB." 
blood product transfusions during hospitalization 
appear in Table II. One 75-year-old patient who had 
pulmonary thromboembolectomy (control group) 
had excessive nonsurgical b eeding and was returned 
to the operating room for wound exploration. This 
patient's 24-bour blood loss was 5875 rel. He re- 
ceived 21 units of packed cells, 29 units of fresh 
frozen plasma, 54 units of platelets, and 20 units of 
cryoprecipitate. His blood losses and transfusion 
history arel excluded from Table II. With this exclu- 
sion there :were no significant differences between 
the two groups in heparin doses, blood loss, or total 
blood product ransfusions, but patients in whom 
coated circuits were used required more protamine 
(p < 0.05)L Two of nine patients had fresh frozen 
plasma and one had platelets in the control group; 
three of 10 had fresh frozen plasma and two had 
platelets in the heparin-coated group. Nineteen 
patients were discharged home. The patient with 
excessive bleeding died of respiratory failure on 
postoperative day 49. 
Changes in measured blood and plasma constitu- 
ents before, during, and after CPB appear in Table 
III and in Figs. 1 and 2. Platelet counts are corrected 
for hemodilution; values for other samples that are 
produced uring CPB are not corrected, but mean 
hematocrit value is given to enable "corrective" 
calculations to be made. In patients in whom hepa- 
rin-coated circuits were used, the corrected platelet 
count is significantly higher 5 minutes after the start 
of CPB than in patients in whom uncoated systems 
were used (Fig. 1). Differences between groups do 
not reach significance after the Bonferroni correc- 
tion at other time points, but by analysis of variance 
the two groups differ significantly (p = 0.001)~ The 
number of circulating platelets decreases ignifi- 
cantly from before CPB in the control group of 
patients at ll subsequent time points and does not 
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20 
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I I P I 
5 Min 30 Min After CPB After 
Protamine 
Fig. 1. Platelet counts depicted as percentage of platelet count obtained before heparin at each time 
interval for each group. Means + standard error. Diamonds indicate control group; squares indicate group 
in which coated circuits were used. See Table III for significant differences within and between groups. 
7 
56 ~ ~  j 
F1.2 4 
nmollL 3 
2 
1 
0 I P I [ 
After 5 Min 30Min After CPB After 
Heparin Protamine 
Fig. 2. Plasma prothrombin fragment F1.2 at each time interval. Means -- standard error. Diamonds 
indicate control group; squares indicate group in which coated circuits were used. There were no significant 
differences between groups. 
decrease significantly in patients in whom coated 
systems were used. Platelet responsiveness to aden- 
osine diphosphate is better preserved in patients in 
whom coated systems were used, and the difference 
between the two groups is significant by analysis of 
variance (p = 0.015). In both groups plasma 
/3-thromboglobulin concentration increases during 
CPB, but there are no significant differences be- 
tween groups at any time nor between the two 
groups by analysis of variance (p = 0.789). 
As compared with "After heparin, before CPB," 
levels of F1.2, thrombin-antithrombin complex, D- 
dimer, and plasmin o~2-antiplasmin complex are 
significantly higher at the end of CPB in both groups 
(Figs. 2 and 3 and Table III). Levels of all of these 
markers of thrombin formation and activity and 
fibrinolytic activity, in addition to fibrinopeptide A 
and tissue plasminogen activator, are significantly 
higher after protamine in both groups. There are no 
significant differences between groups for any of these 
rnarkers at any time point. Further, there are no 
significant differences between groups for markers 
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TAT 
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Fig. 3. Plasma thrombin-antithrombin complex (TAT) at each time interval. Means _+ standard error. 
Diamonds indicate control group; squares indicate group in which coated circuits were used. There were no 
significant differences between groups. 
of thrombin formation by analysis of variance (Table 
III). The concentration of neutrophil elastase in- 
creases by the end of CPB in both groups; inacti- 
vated complement 3b concentration does not in- 
crease during CPB and actually decreases early after 
CPB starts in all patients. With the exception of 
plasmin o~2-antiplasmin complex, there are no signif- 
icant differences between groups by either the t
statistic or analysis of variance. 
Results of RIA measurements of surface-ad- 
sorbed proteins appear in Fig. 4. Significantly more 
antithrombin is adsorbed onto heparin-coated sur- 
faces than onto uncoated surfaces. There are no 
significant differences between the amounts of other 
surface-adsorbed proteins between groups and no 
significant differences for any adsorbed protein be- 
tween venous and arterial tubing samples. 
Discussion 
This study fails to show that heparin-coated ex- 
tracorporeal perfusion circuits reduce any plasma 
markers of thrombin formation and activity or any 
markers of fibrinolytic activity during cardiac oper- 
ations; therefore we conclude that surface-bound 
heparin dges not have an additional anticoagulant 
effect greater than that produced by standard oses 
of systemic heparin on soluble coagulation proteins 
in vivo. These data and this conclusion confirm and 
extend the findings of Korn and colleagues 11and 
Wagner and coworkers, 27 who also found no evi- 
dence of anticoagulant activity of surface-bound 
heparin in:vitro or in vivo. Wagner's group studied 
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Fig. 4. RIA for detection of adsorbed proteins on sur- 
faces of arterial and venous tubing (n = 24). Data are 
expressed as counts per minute x 10 3 --+ standard error of 
the mean of secondary 12»I- labeled goat antirabbit mmu- 
noglobulin G binding to primary antibodies (rabbit anti- 
human immunoglobulin G) to antithrombin (AT), fibrin- 
ogen (FB), factor XII (XII), von Willebrand factor (vWF), 
or PBS control (CON). *p < 0.05 by Student's unpaired t 
statistic between groups. 
patients with first-time isolated myocardial revascu- 
larization operations and used perfusion circuits 
that lacked the heparin coating on the cardiotomy 
reservoir system; however, their data, taken at more 
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frequent sampling times, are similar to these with 
completely heparinized circuits. Although all 
three studies (Korn's, Wagner's, and this one) 
used the Carmeda process, the findings are un- 
likely to differ with ionic bound heparin coatings 
except for heparin leaching from the latter cir- 
cuits.10, 2s In vitro, the competing Duraflo II hep- 
arin coating (Bentley Laboratories Division, Ir- 
vine, Calif.) leaches approximately 15% of the 
surface-bound heparin into saline solution within 
4 hours. 2a Because surface-bound heparin has no 
demonstrable additional anticoagulant effect, we 
believe that reduction of systemic heparin 9'12, 13 is 
unwise and may risk thrombosis and embolism 
during the operation. 29
In vitro studies how that covalently bound sur- 
face heparin does bind antithrombin and catalyzes 
antithrombin binding to factor Xa 3° and to throm- 
bin. 31 Furthermore, thrombin binds to surface-ad- 
sorbed antithrombin 32 and may bind to surface- 
adsorbed heparin. Surface-adsorbed thrombin does 
not block the ability of surface-bound heparin to 
bind more antithrombin when more antithrombin s 
introduced into the system. 31 These data are consis- 
tent with the increased surface antithrombin mea- 
sured by RIA on the coated circuits in the current 
study. Normally, heparin catalyzes the binding of 
antithrombin to thrombin and is not consumed 
in the process. The in vitro studies 3°'31 indicate 
that coated surfaces bind thrombin, but it is not 
clear27, 3~, 33 that the covalently bonded thrombin- 
antithrombin complex is released by bound heparin. 
If surface heparin releases thrombin-antithrombin 
complex, we expect o see higher concentrations of 
plasma thrombin-antithrombin complex associated 
with the heparin-coated circuits because thrombin is 
progressively produced uring CPB. No study (ref- 
erences 27, 32, 33, and this study) has shown higher 
plasma concentrations of thrombin-antithrombin 
complex at any time during CPB. This study shows 
nonsignificantly reduced plasma concentrations of 
thrombin-antithrombin complex during the initial 
period of CPB, but nearly identical concentrations 
at the end of CPB. Gu, 32 Pradhan, 33 and their 
colleagues found reduced plasma thrombin-anti- 
thrombin complex throughout CPB, but these inves- 
tigators did not measure markers of thrombin for- 
mation. The absence of significant differences in 
plasma F1.2 and thrombin-antithrombin complex 
concentrations i  this and Wagner's tudy 27 are most 
consistent with the conclusion that surface-bound hep- 
arin does not produce an additional anticoagulant 
effect greater than that produced by standard oses of 
systemic heparin during clinical CPB. 
Subsequent prospective, randomized, controlled 
studies in patients with coated perfusion circuits and 
reduced levels of systemic heparin may or may not 
show reduction in both plasma F1.2 and thrombin- 
antithrombin complex concentrations during CPB; 
if reductions of both markers occur, the conclusion 
that coated surfaces produce an anticoagulant effect 
is justified. However, to dispel the concerns that 
thrombin-antithrombin complex may not be re- 
leased from the coated surface and that the coated 
surface may become saturated with thrombin-anti- 
thrombin complex and unable to bind additional 
thrombin, both markers taust remain significantly 
less than plasma concentrations in control subjects 
treated with a standard ose of heparin and an 
uncoated circuit for the full duration of CPB. 
Surface-bound heparin alters the composition of 
surface-adsorbed proteins, changes ome character- 
istics of the resulting protein mosaic, and is not 
completely buried by adsorbed plasma proteins. 34 
As mentioned earlier, we find more antithrombin on 
coated surfaces by RIA. We also find significantly 
higher platelet counts and greater platelet sensitivity 
to adenosine diphosphate during CPB in patients in 
whom coated circuits were used. Wagner and col- 
leagues 27 find nonsignificantly less 13-thromboglobu- 
lin release with coated perfusion circuits. These 
observations are consistent with those of in vitro 
studies, 11'35 but other investigators 6'12'27 do not 
observe reduced platelet adhesiveness with clinical 
applications of heparin-coated surfaces. Thus the 
effect of heparin coatings on platelets remains un- 
settled. 
Some investigators find less activation of neutro- 
phils 7, 36-38; others,33 including us, do not. Three 
groups report reductions in markers of complement 
activation at various and often different sampling 
times during and immediately after cardiac opera- 
tions.6, 7, 9, 38 These data suggest that surface-bound 
heparin may alter the reactivity of some blood 
elements with circuit surfaces in vivo and may 
possibly reduce mediators 39of the "whole body" 
inflammatory esponse. 4°However, the magnitude, 
significance, and importance of these effects, which 
are not related to coagulation, remain unclear. 
In the practice of cardiothoracic surgery, special 
circumstances occasionally arise wherein adminis- 
tration of systemic heparin is or may be dangerous 
because of bleeding risks that are remote from the 
surgical field. Under these circumstances, surgeons 
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may choose not to use systemic heparin or to reduce 
the dose as the lesser of competing risks. Although 
this option is not supported by this and Wagner's 
study, a7 there are anecdotal reports of successful use 
of heparin-coated circuits in most applications, 4a44 
but not all. 29 
The mechanisms by which thrombin is formed 
during cardiac operations are still being studied 
and argued. There is evidence that both the intrin- 
sic 45"46a nd extrinsic 47-48a coagulation pathways are 
involved; the relative importance of each is dis- 
pute& There is also substantial evidence that hepa- 
rin is an agonist for platelets, 49'5° complement 
activation, 51 and neutrophils. 45' 52 Putting these is- 
sues aside, there is universal agreement that cardiac 
operations produce a massive thrombotic stimu- 
lus 1, 2 that must be suppressed by high concentra- 
tions of heparin. Whether surface-bound heparin 
circuits are raore thromboresistant than uncoated 
circuits or whether they reduce the "whole body 
inflammatory response" is irrelevant if coated sur- 
faces do not produce a meaningful and reliable 
anticoagulant effect in vivo when doses of systemic 
heparin are reduced. 
After presentation before The American Associ- 
ation for Thoracic Surgery and in peer review, this 
study was criticized for small sample size and lack of 
statistical power. It should be pointed out that the 
biochemical assays and surface protein maps used in
this study are both sophisticated and expensive, and 
they address the issue of thrombin formation with 
the most powerful methods currently available. Sta- 
tistical power is influenced by both sample size and 
the magnitude of the differences between means. 
When observed ifferences are large (e.g., platelet 
counts in this study), the power value is large (e.g., 
0.986 for these platelet counts) even though the 
sample size is small. Power is primarily used to 
design studies to determine how many samples are 
needed to prove or disprove a chosen difference 
between groups, which the investigator arbitrarily 
decides is meaningful and important. Our group 
could not decide what differences to choose, be- 
cause CPB alters all of the parameters studied and 
all of the alterations are undesirable. 
This argument, however, misses the point and 
purpose of this study. Our group became concerned 
that perfusion was being done with coated circuits 
and half the standard ose of heparin, despite the 
t . 
absence of pnor, reliable measurements of thrombin 
formation. The most important point that the study 
makes is tllat the efficacy of heparin-coated circuitry to 
reduce thrombin formation and activity during CPB 
has not been dernonstrated. The burden of proof in 
science is to demonstrate a phenomenon, in this case 
that heparin coatings reduce thrombin formation and 
activity. The null hypothesis is accepted until it is 
shown with high probability to be false. No scientist 
has ever proved that a phenomenon does not happen. 
As a reviewer noted, "absence of proof is not proof of 
absence." We agree, but we hope that cardiac sur- 
geons will not abandon science for theology. 
We thank Doreen Cowie, Matt Robertson, and Robert 
Helgans for their valuable help and Medtronic Inc. for the 
heparin-coated circuits. 
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Discussion 
Dr. Shukri F. Khuri (West Roxbury, Mass.). The 
strength of this work is that it directs to an unsettled field 
of investigation a host of much needed state-of-the-art 
hematologic assays, providing us with a compendium of 
end points that should enhance our understanding of the 
prosthetic surfaces-blood interface. 
My main concern about this study relates to the rela- 
tively small sample size, 10 patients in each group, and its 
impact on the interpretation of the data. The study 
concluded that heparin-coated circuits did not offer an 
advantage over conventional circuits mainly because, in 
the course of CPB, they did not effect a significant 
reduction in the degree of thrombin formation (as as- 
sessed by thrombin-antithrombin complex, fibrinopeptide 
A, and prothrombin fragment F1.2) or fibrinolysis (as- 
sessed with D-dimer, tissue plasminogen activator, plas- 
minogen activator inhibitor-1, and plasmin c~2-antiplasmin 
complex. The authors did not provide power statistics to 
ensure against ype II statistical errors. A close examina- 
tion of Table III shows that trends in favor of the heparin- 
coated surfaces were observed in all but one of these 
parameters atthe 30-minute CPB time point. Considering 
the relatively small size of the two patient groups, how can 
the authors assure us that the lack of statistical signifi- 
cance that they attributed to these trends was not a 
reflection of a type II statistical error? 
I also have concerns about the lack of correction of the 
concentration of the various proteins for the significant 
amount of hemodilution that must have occurred with the 
institution of CPB. Systemic hypothermia, the extent of 
which varied widely in these patients, was also not shown 
to be comparable in the two groups. Data from our 
institution lead us to hypothesize that the salutary hema- 
tologic effects of heparin-coated circuits are best realized 
under normothermic conditions. Could the wide range of 
systemic hypothermia encountered in this study have 
blunted the salutary effect of the heparin-coated circuit? 
Last, considering that heparin per se, independent of 
CPB, has been shown to cause significant platelet dysfunc- 
tion and increased fibrinolysis, there may be a clinical 
advantage in using lower doses of heparin with heparin- 
coated surfaces, particularly in relation to the reduction of 
postoperative blood loss. In their discussion, the authors 
categorically reject his option. However, the trends in the 
hematologic parameters they reported, in the face of their 
relatively small patient sample size, did not justify this 
rejection. The efforts to evaluate this potentially attractive 
clinical option need not be stymied by the data provided. 
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Dr. Gorman, and his colleagues have initiated a healthy 
scientific discourse that should improve our understand- 
ing of the biology of heparin-coated circuitry. 
Dr. Gorman. You raise three concerns: the chance the 
null hypothesis will be accepted when in fact it is false 
(type II error), the impact of hemodilution, and the 
impact of hypothermia on our measurements. Although 
relatively small sample size does reduce the power of 
statistical calculations for detecting type II errors, moder- 
ately low power values do not establish a high probability, 
for example p < 0.05, that two means are different. In 
other words, a power value of 0.5 means there is a 50% 
chance that two means are different, but that chance is far 
too low to conclude that there is a difference. Heparin- 
coated circuits bear the burden of proving efficacy; other- 
wise we are discussing theology and not science. When 
one looks at all of our data and particularly data taken at 
the end of bypass, when power values are generally high 
despite small sample sizes, one does not see any evidence 
that heparin-coated circuitry reduces thrombin formation 
or activity. This is our primary message; heparin coatings 
may or may not alter other blood constituents, but our 
data show no clear effect on thrombin formation and 
activity. 
Correction for hemodilution raises reported values 
above concentrations that are actually circulating. Correc- 
tions for hemodilution are more important for within- 
group changes than for between group comparisons be- 
cause the degree of hemodilution is the same in both 
groups. We have added hematocrit values to the published 
table to enable interested parties to do their own correc- 
tions. 
We have no data regarding the efficacy of heparin- 
coated perfusion circuits during normothermic perfusions. 
Dr. George J. Magovern (Pittsburgh, Pa.). At an acti- 
vated clotting time of 400 seconds or longer, it appears 
that the Carmeda coating confers no benefit with regard 
to thrombin resistance. Allegheny General Hospital has 
had some spectacular successes using this coating in the 
setting of postcardiotomy shock, and we most recently 
were able to use the coating and the device for 14 days in 
a venoarterial mode for a patient who had lung graft 
failure after a double lung transplant, and he recovered 
and has survived. We have used the coating and the device 
with a much lower activated clotting time, and I am 
wondering whether there would have been significant 
differences between the groups if you had monitored your 
two groups with lower activated clotting times. 
Dr. Gorman. That is a possibility, but we chose not to 
reduce activated clotting times until we had more evi- 
dence that heparin-coated surfaces impair blood clotting. 
Dr. Ronald C. Hill (Morgantown, W.Va.). These are 
interesting data. We have had extensive xperience with 
this system clinically and used it with low heparin acti- 
vated clotting times, activated clotting times in the range 
of 200 seconds, and have had no clinical problems with it. 
My questions are as follows: Did you use a pump suction 
or cardiotomy in this system and did you recirculate after 
weaning from CPB? If you did use suction or cardiotomy 
or did not recirculate, you may have stimulated the 
coagulation complement system. Indeed, we discontinue 
CPB at about 2 1/min and then immediately recirculate. 
Also, did you use a biopump? I noticed that you used the 
system in only four or five coronaries, which is a closed 
system. Everything else you used was an open system. I 
would be interested in how you devised your vent system 
to eliminate the air interface. 
Dr. Edmunds. We used both cardiotomy and vent 
suction produced by roller pumps and a cell salvage 
system using vacuum suction. We did not recirculate 
during weaning of CPB or afterwards. All patients re- 
ceived full heparinization, and it is unlikely that recircu- 
lation would alter our results in any way. 
Dr. Ludwig K. von Segesser (Zurich, Switzerland). Un- 
fortunately, CPB today does not consist only of CPB. A 
number of systems are added to it: a blood cardioplegia 
system, cardiotomy suction and/or cell salvage devices, 
hemofilters, and others. My questions to the authors are 
these: What type of cardioplegia did you use in your 
study? How did you measure the volume retransfused to
the patient? In the coated group four patients had valve 
type surgery, in which we have to expect much more 
retransfusion volume, so the comparison could be difficult. 
Finally, I find that in your results the thrombin-antithrom- 
bin complex values, for instauce, are quite different for the 
first 30 minutcs of CPB and change afterward. That is just 
the time at which we normally start to use cardiotomy 
suction, or, in your case, a cell salvage device. 
Dr. Ednmnds. We agree completely that the modern 
heart-lung machine is composed of many subsystems to 
which blood is exposed. In this study all of these systems 
were heparin coated in the experimental group except for 
the Cell Saver System. Only washed red cells were re- 
turned from this system. We used antegrade and retro- 
grade cold blood cardioplegia nd made no attempt o 
measure reinfused volumes. We agree that the qualita- 
tively lower thrombin-antithrombin complex values at 5 
and 30 minutes in patients in whom coated circuits were 
used and the demonstration that antithrombin III is 
adsorbed onto these surfaces uggest hat the surface is 
binding thrombin. The F1.2 values, however, indicate no 
change in thrombin formation. These data raise the 
question of whether heparin-coated surfaces are able to 
release the thrombin-antithrombin complex and whether 
they become saturated with bound thrombin over time. 
